Advanced search
Publication Cover
Postgraduate Medicine Volume 130, 2018 - Issue 6
Submit an article Journal homepage
436
Views
7
CrossRef citations to date
0
Altmetric
Clinical Features - Original Research

Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties

Hui G. ChengDepartment of Epidemiology and Biostatistics, Michigan State University, East LansingUSACorrespondence[email protected]
View further author information
&
Paul M. CoplanPurdue Pharma LP, StamfordCT, USA;Adjunct, Department of Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, PhiladelphiaUSAView further author information
Pages 568-574 | Received 08 May 2018, Accepted 20 Jun 2018, Published online: 16 Jul 2018

References

  • Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574.
  • Rudd RA, Aleshire N, Zibbell JE, et al. Increases in drug and opioid overdose deaths — United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382.
  • Dart RC, Severtson SG, Bucher-Bartelson B. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(16):1573–1574.
  • Sellers EM, Perrino PJ, Colucci SV, et al. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27(9):808–816.
  • OxyContin [package insert]. Stamford CT: purdue Pharma L.P; 2007 [cited 2018 Jun 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022272s027lbl.pdf
  • Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.
  • Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100(3):275–286.
  • Hwang CS, Chang HY, Alexander GC. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf. 2015;24(2):197–204.
  • Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from Oxycontin. JAMA Psychiatry. 2015;72(5):424–430.
  • Freeman J, Hutchinson G. Prevalence, incidence and duration. Am J Epidemiol. 1980;112(5):707–724.
  • Kramer M. A discussion of the concepts of incidence and prevalence as related to epidemiologic studies of mental disorders. Am J Public Health Nations Health. 1957;47(7):826–840.
  • Lapouse R. Problems in studying the prevalence of psychiatric disorder. Am J Public Health Nations Health. 1967;57(6):947–954.
  • Holford TR. Age-period-cohort analysis. Wiley Stats Ref Stat. Ref. Online 1–25. 2016. DOI:10.1002/9781118445112.stat06122.pub2
  • McCarthy M. Obama outlines plan to curb prescription drug and heroin misuse. BMJ. 2015;351:h5656.
  • Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health: summary of Methodological Studies – 1971–2014; [cited 2018 Jan 18]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUHmethodsSummary2013/NSDUHmethodsSummary2013.pdf
  • Cheng HG, Cantave MD, Anthony JC. Taking the first full drink: epidemiological evidence on male-female differences in the United States. Alcohol Clin Exp Res. 2016;40(4):816–825.
  • Cheng HG, Cantave MD, Anthony JC. Alcohol experiences viewed mutoscopically: newly incident drinking of twelve- to twenty-five-year-olds in the United States, 2002-2013. J Stud Alcohol Drugs. 2016;77(3):405–412.
  • Cheng HG, Anthony JC. Does our legal minimum drinking age modulate risk of first heavy drinking episode soon after drinking onset? Epidemiological evidence for the United States, 2006–2014. PeerJ. 2016;4:e2153.
  • Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017 Feb 1;46(1):348–355.
  • Yang Y, Schulhofer-Wohl S, Fu WJ, et al. The intrinsic estimator for age-period-cohort analysis: what it is and how to use it. AJS. 2008;113(6):1697–1736.
  • Deandrea DC, Troost JP, Anthony JC. Toward primary prevention of extra-medical OxyContin® use among young people. Prev Med. 2013 Sep;57(3):244–246.
  • Jones CM, Muhuri PK, Lurie PG. Trends in the nonmedical use of OxyContin, United States, 2006 to 2013. Clin J Pain. 2017;33(5):452–461.
  • Severtson SG, Ellis MS, Kurtz SP. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;168:219–229.
  • Sessler NE, Downing JM, Kale H, et al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238–1246.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.